Skip to main content
Professional Technical IVT

lipoprotein-associated phospholipase A2

Pronunciation: LIE-poh-pro-teen

Inflammatory biomarker associated with atherosclerotic plaque vulnerability and cardiovascular risk.

Full Definition

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme produced by inflammatory cells within atherosclerotic plaques that hydrolyzes oxidized phospholipids, generating pro-inflammatory and pro-atherogenic mediators. Elevated plasma Lp-PLA2 levels and activity are associated with increased cardiovascular risk, particularly stroke risk, independent of traditional risk factors. While initially considered a promising biomarker for risk stratification, recent guidelines have de-emphasized its clinical utility due to mixed results from intervention trials targeting this pathway. Lp-PLA2 testing may still be considered in select intermediate-risk patients for additional risk stratification.

Usage

Usage note: Often abbreviated as Lp-PLA2; note the hyphen in the abbreviation.

In Context

  • "Elevated lipoprotein-associated phospholipase A2 levels suggested increased plaque vulnerability." — cardiovascular risk assessment
  • "The role of Lp-PLA2 testing in routine clinical practice remains controversial." — laboratory medicine review

Also known as

Lp-PLA2 PLAC test

Don't confuse with

phospholipase C secretory phospholipase A2

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON